BiomX Inc.

Practice Area: 
Stock Symbol: 
Case Status: 

Ademi LLP is investigating BiomX (NYSE American: PHGE) for possible breaches of fiduciary duty and other violations of law in its transaction with Adaptive Phage Therapeutics.

In the transaction, BiomX will issue 9,164,967 shares of BiomX common stock, 40,471 shares of Series X Preferred Stock convertible into 40,471,000 shares of BiomX common stock and warrants exercisable for 2,166,497 shares of BiomX common stock.   

We are investigating the conduct of BiomX’s board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.